TTI Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Thiogenesis Therapeutics (CVE: TTI)
›
Thiogenesis Therapeutics (CVE: TTI) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.5900 CAD on 18 November 2026, down 20.3% over 52 weeks. Its 52-week range is 0.4400 CAD to 0.7200 CAD: the price is 18.1% below the high and 34.1% above the low.
Its market capitalisation is 41.29M CAD.
Thiogenesis Therapeutics reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.27M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.